Using Experience Sampling Methodology Data to Characterize the Substance Use of Youth With or At-Risk of Psychosis.

Autor:	Weiss DM; Maine Medical Center Research Institute, MaineHealth, Portland, ME, United States., Bernier E; Maine Medical Center Research Institute, MaineHealth, Portland, ME, United States., Robbins DR; Maine Medical Center Research Institute, MaineHealth, Portland, ME, United States.; Department of Psychiatry, Tufts University School of Medicine, Boston, MA, United States., Elacqua KM; Maine Medical Center Research Institute, MaineHealth, Portland, ME, United States., Johnson KA; Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston, MA, United States., Powers K; Maine Medical Center Research Institute, MaineHealth, Portland, ME, United States., Mesholam-Gately RI; Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston, MA, United States.; Department of Psychiatry, Harvard Medical School, Boston, MA, United States., Woodberry KA; Maine Medical Center Research Institute, MaineHealth, Portland, ME, United States.; Department of Psychiatry, Tufts University School of Medicine, Boston, MA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2022 May 03; Vol. 13, pp. 874246. Date of Electronic Publication: 2022 May 03 (Print Publication: 2022).
DOI:	10.3389/fpsyt.2022.874246
Abstrakt:	Objectives: Psychotic-spectrum disorders emerge during adolescence and early adulthood, which corresponds with the peak period for substance use initiation. Clinical and epidemiological data provide support that substance use is associated with psychotic symptom onset and severity. Experience-sampling methodology (ESM) data may provide additional insight into dynamic associations between substance use and psychotic symptoms. This is one of the first efforts to characterize substance use frequency and dynamic associations with psychotic symptoms and negative affect from ESM data in both clinical high risk (CHR) and early psychosis (EP) individuals. Methods: Using ESM, 33 individuals, including 17 with CHR and 16 EP (age range: 15-24), provided information on substance use, negative affect, and psychotic symptoms 6 times a day across a 21-day data collection window. Psychotic symptoms and negative affect included multi-item variables rated on a seven-point Likert Scale. Participants reported recent substance use for 4 drug classes (nicotine, cannabis, depressants, stimulants) via a yes/no item. Descriptive information included data on substance use frequency, and momentary negative affect and psychotic symptoms. Exploratory analyses included multi-level and person-level dynamic structural equation models, which assessed contemporaneous and lagged associations between substance use and symptoms. Results: Twenty-seven individuals (82%) reported recurrent substance use including stimulants ( n = 12, 46%), nicotine ( n = 9, 27%), cannabis ( n = 6, 18%), and depressants ( n = 4, 12%). Individuals with any recurrent substance use indicated usage at 47.7% of answered prompts; stimulants at 23.6%; nicotine at 74.2%; cannabis at 39.1%; and depressants at 20.1%. A multi-level dynamic structural equation model reflected that substance use (any class) was associated with lagged negative affect (β = -0.02, CI: -0.06, < -0.00) but no significant contemporaneous or lagged associations between substance use and psychotic symptoms. Person-level models suggest potentially meaningful inter-individual variability. Conclusions: CHR and EP individuals use a range of substances that may both reflect and influence other experiences in daily life experiences. Data reflected moderate to high rates of recurrent substance use with more consistent use within nicotine and cannabis classes. ESM data have the potential to increase our understanding of the dynamic relationships between substance use and symptoms and to inform treatment for individuals in early course psychosis. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Weiss, Bernier, Robbins, Elacqua, Johnson, Powers, Mesholam-Gately and Woodberry.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu